Letrozol Denk

Letrozole, the active ingredient in Letrozol Denk, is an aromatase inhibitor presented as an oral formulation for oral use. It is employed in the endocrine treatment of hormone receptor‑positive breast cancer in postmenopausal women. By lowering estrogen production, it helps to slow tumor growth and improve clinical outcomes.

GNH USA supplies Letrozol Denk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Letrozole is used in the management of hormone‑dependent breast cancer, targeting estrogen‑driven tumor growth.

- Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen levels to inhibit tumor progression. - Metastatic breast cancer in postmenopausal women: helps control disease spread. - Adjuvant therapy for early‑stage disease: improves disease‑free survival.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Joint pain: aching or stiffness in joints. - Fatigue: persistent tiredness. - Nausea: upset stomach and urge to vomit. - Headache: mild to moderate head discomfort. - Increased cholesterol: elevation of serum lipid levels.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Bone fracture: increased risk due to bone density loss. - Deep vein thrombosis: clot formation in deep veins. - Pulmonary embolism: blockage of pulmonary arteries. - Allergic reactions: rash, swelling, or anaphylaxis. - Myocardial infarction: heart attack.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Monitor bone health: assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Check liver function: perform baseline and periodic liver enzyme tests. - Assess cardiovascular risk: monitor lipid profile and blood pressure. - Avoid use in pregnancy: teratogenic, contraindicated. - Discontinue if severe adverse reactions occur. - Store at ambient temperature: keep in original container, protect from moisture and light.

Letrozole can interact with other medicines that affect its metabolism or hormonal pathways.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: may reduce efficacy of letrozole. - Strong CYP2C19 inhibitors (e.g., fluconazole): increase plasma levels of letrozole. - Strong CYP2C19 inducers (e.g., rifampicin): decrease plasma levels of letrozole.

Moderate Interactions (Monitor Closely): - Warfarin: may alter anticoagulant effect, monitor INR. - Tamoxifen: potential antagonistic effect on estrogen pathways. - Antidepressants (SSRIs): may affect metabolism, observe for side effects.